Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary Shujin Jianyao Pills approved for clinical trials
Baiyunshan (600332.SH) announced that recently, its subsidiary Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd. (referred to as "Chenliji Pharmaceutical Factory") received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the additional indications for Shujin Jianyao Pills. The clinical trial of this product for the treatment of lumbar disc herniation with liver and kidney deficiency and wind-dampness stasis syndrome is approved.
Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that recently, its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Chenliji Pharmaceutical Factory Co., Ltd. (referred to as "Chenliji Pharmaceutical Factory") received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the additional indications for Shujin Jianyao Pills. The product is approved to conduct clinical trials for lumbar disc herniation with liver and kidney deficiency and wind-dampness stasis syndrome.
Related Articles
Midea Group Co., Ltd (00300) repurchased 1,075,300 A shares on October 12 for approximately RMB 89.9143 million.
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,800 on October 12.
CHINA HONGBAO (08316) changes its name to "Sujiao Suidao Life Holdings Limited"
Midea Group Co., Ltd (00300) repurchased 1,075,300 A shares on October 12 for approximately RMB 89.9143 million.
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,800 on October 12.
CHINA HONGBAO (08316) changes its name to "Sujiao Suidao Life Holdings Limited"
